Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

• Status: Unknown status
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether moxonidine is effective in reducing urine albumin levels in patients with diabetic kidney disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baker Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
• Treatments: Moxonidine

Criteria

Inclusion Criteria:

• age: 18-75 years

• diabetic nephropathy as defined by the mean of three consecutive early morning urinary albumin-creatinine ratios (UACR) of >300mg per gram, or > 200mg per gram in patients receiving therapy targeted at blockade of the RAS

Exclusion Criteria:

• non-diabetic kidney disease

• UACR of more than 3500mg per gram, an estimated glomerular filtration rate of less than 30ml/min/1.73m2.

• chronic urinary tract infection.

• severe hypertension

• heart failure NYHA class II-IV

• major cardiovascular disease within the previous 6 months

• left ventricular ejection fraction <55%